This is the podcast site for iForumRx.org - a community of ambulatory care pharmacy specialists and others interested in the evidence regarding drug therapy and patient management.
All content for iForumRx.org is the property of University of Mississippi School of Pharmacy and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This is the podcast site for iForumRx.org - a community of ambulatory care pharmacy specialists and others interested in the evidence regarding drug therapy and patient management.
Semaglutide for CKD – Does the FLOW trial impact the standard of care?
iForumRx.org
21 minutes 15 seconds
1 year ago
Semaglutide for CKD – Does the FLOW trial impact the standard of care?
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are one of the established treatments used to slow the progression of CKD and improve outcomes. Could perhaps the glucagon-like peptide 1 (GLP-1) receptor agonists provide similar, additive, or different benefits in patients with CKD?
Guest Author: John Swegle, PharmD, BCPS, BCACP
Music by Good Talk
iForumRx.org
This is the podcast site for iForumRx.org - a community of ambulatory care pharmacy specialists and others interested in the evidence regarding drug therapy and patient management.
